ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Bharat Parenterals Ltd reported revenue from operations of ₹99.6 Cr (-4.2% YoY) and a net loss of ₹8.2 Cr for Q4 FY26.
Bharat Parenterals reported FY26 consolidated revenue of ₹345.4 Crore and recommended a ₹0.07 Crore dividend. The board also re-appointed cost and internal auditors.
Bharat Parenterals Limited scheduled a board meeting for May 18, 2026. Directors will consider FY2026 audited financial results and recommend a final equity dividend.
Bharat Parenterals Limited (BSE: 541096) confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026. The company reported outstanding borrowings of ₹15.77 Crore, which is below the threshold for mandatory debt-market borrowing requirements under SEBI circulars.
Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, concluded a U.S. FDA inspection at its Vadodara facility with five procedural observations under a Voluntary Action Indicated (VAI) classification. The inspection occurred in April 2026. The company maintains its commitment to quality standards and will submit responses within prescribed timelines.
Bharat Parenterals Ltd clarified to the BSE that recent stock price movements are market-driven. The company confirmed it has no undisclosed material information or impending announcements that could impact price or volume behavior and remains in compliance with SEBI Listing Regulations.
Bharat Parenterals Ltd reported a net loss of ₹9.7 Cr for Q3 FY26.
Bharat Parenterals Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent, Adroit Corporate Services, confirmed that securities received for dematerialisation were processed and listed on stock exchanges within the mandated 15-day period.